Median progression-free survival (PFS): 5.8 months with MARGENZA plus chemotherapy compared with 4.9 months with trastuzumab plus chemotherapy; hazard ratio=0.76 (95% confidence interval, 0.59-0.98), P=0.0331
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
HER2-positive = human epidermal growth factor receptor 2 positive
The efficacy and safety of MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy was evaluated in SOPHIA, a randomized, multicenter, open-label trial of 536 metastatic HER2-positive breast cancer patients (IHC 3+ or ISH-amplified HER2+) who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.1
aIn the SOPHIA trial, investigators were able to pair MARGENZA with a choice of 4 chemotherapy options, including capecitabine, eribulin, gemcitabine, and vinorelbine.1
1. MARGENZA Prescribing Information. MacroGenics, Inc.; 2020.
Median progression-free survival (PFS): 5.8 months with MARGENZA plus chemotherapy compared with 4.9 months with trastuzumab plus chemotherapy; hazard ratio=0.76 (95% confidence interval, 0.59-0.98), P=0.0331
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Omnichannel content section 2
HER2-positive = human epidermal growth factor receptor 2 positive
The efficacy and safety of MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy was evaluated in SOPHIA, a randomized, multicenter, open-label trial of 536 metastatic HER2-positive breast cancer patients (IHC 3+ or ISH-amplified HER2+) who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.1
aIn the SOPHIA trial, investigators were able to pair MARGENZA with a choice of 4 chemotherapy options, including capecitabine, eribulin, gemcitabine, and vinorelbine.1
1. MARGENZA Prescribing Information. MacroGenics, Inc.; 2020.
Median progression-free survival (PFS): 5.8 months with MARGENZA plus chemotherapy compared with 4.9 months with trastuzumab plus chemotherapy; hazard ratio=0.76 (95% confidence interval, 0.59-0.98), P=0.0331
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Omnichannel content section 3
HER2-positive = human epidermal growth factor receptor 2 positive
The efficacy and safety of MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy was evaluated in SOPHIA, a randomized, multicenter, open-label trial of 536 metastatic HER2-positive breast cancer patients (IHC 3+ or ISH-amplified HER2+) who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.1
aIn the SOPHIA trial, investigators were able to pair MARGENZA with a choice of 4 chemotherapy options, including capecitabine, eribulin, gemcitabine, and vinorelbine.1
1. MARGENZA Prescribing Information. MacroGenics, Inc.; 2020.
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
Important Information
You are about to go to a website that is operated by an independent third party. Your activities on the external website will be managed by its policies and practices. By clicking “Continue,” you will go to the external website.